BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11506492)

  • 21. Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas.
    Ambros PF; Ambros IM; Kerbl R; Luegmayr A; Rumpler S; Ladenstein R; Amann G; Kovar H; Horcher E; De Bernardi B; Michon J; Gadner H
    Med Pediatr Oncol; 2001 Jan; 36(1):1-4. PubMed ID: 11464855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.
    Villamón E; Berbegall AP; Piqueras M; Tadeo I; Castel V; Djos A; Martinsson T; Navarro S; Noguera R
    PLoS One; 2013; 8(1):e53740. PubMed ID: 23341988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays.
    George RE; Attiyeh EF; Li S; Moreau LA; Neuberg D; Li C; Fox EA; Meyerson M; Diller L; Fortina P; Look AT; Maris JM
    PLoS One; 2007 Feb; 2(2):e255. PubMed ID: 17327916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.
    Cetinkaya C; Martinsson T; Sandgren J; Träger C; Kogner P; Dumanski J; Díaz de Ståhl T; Hedborg F
    BMC Cancer; 2013 May; 13():231. PubMed ID: 23656755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroblastoma--clinical applications of molecular parameters.
    Brodeur GM
    Brain Pathol; 1990 Sep; 1(1):47-54. PubMed ID: 1669693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene signatures associated with genomic aberrations predict prognosis in neuroblastoma.
    He X; Qin C; Zhao Y; Zou L; Zhao H; Cheng C
    Cancer Commun (Lond); 2020 Mar; 40(2-3):105-118. PubMed ID: 32237073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
    Caron H; van Sluis P; de Kraker J; Bökkerink J; Egeler M; Laureys G; Slater R; Westerveld A; Voûte PA; Versteeg R
    N Engl J Med; 1996 Jan; 334(4):225-30. PubMed ID: 8531999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
    Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
    Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene.
    Ejeskär K; Aburatani H; Abrahamsson J; Kogner P; Martinsson T
    Br J Cancer; 1998 Jun; 77(11):1787-91. PubMed ID: 9667647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.
    Carén H; Erichsen J; Olsson L; Enerbäck C; Sjöberg RM; Abrahamsson J; Kogner P; Martinsson T
    BMC Genomics; 2008 Jul; 9():353. PubMed ID: 18664255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
    Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
    J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms.
    Martinsson T; Sjöberg RM; Hedborg F; Kogner P
    Cancer Res; 1995 Dec; 55(23):5681-6. PubMed ID: 7585654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
    Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M
    J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interstitial and large chromosome 1p deletion occurs in localized and disseminated neuroblastomas and predicts an unfavourable outcome.
    Iolascon A; Lo Cunsolo C; Giordani L; Cusano R; Mazzocco K; Boumgartner M; Ghisellini P; Faienza MF; Boni L; De Bernardi B; Conte M; Romeo G; Tonini GP
    Cancer Lett; 1998 Aug; 130(1-2):83-92. PubMed ID: 9751260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allelotype of neuroblastoma.
    Takita J; Hayashi Y; Kohno T; Shiseki M; Yamaguchi N; Hanada R; Yamamoto K; Yokota J
    Oncogene; 1995 Nov; 11(9):1829-34. PubMed ID: 7478611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease.
    Mora J; Cheung NK; Chen L; Qin J; Gerald W
    Cancer; 2001 Jan; 91(2):435-42. PubMed ID: 11180092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy.
    Passariello A; De Brasi D; Defferrari R; Genesio R; Tufano M; Mazzocco K; Capasso M; Migliorati R; Martinsson T; Siani P; Nitsch L; Tonini GP
    Eur J Med Genet; 2013 Nov; 56(11):626-34. PubMed ID: 24035971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioinformatics analysis of miRNAs in the neuroblastoma 11q-deleted region reveals a role of miR-548l in both 11q-deleted and MYCN amplified tumour cells.
    Jurcevic S; Keane S; Borgmästars E; Lubovac-Pilav Z; Ejeskär K
    Sci Rep; 2022 Nov; 12(1):19729. PubMed ID: 36396668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amplification of the MYCN oncogene and deletion of putative tumour suppressor gene in human neuroblastomas.
    Schwab M
    Brain Pathol; 1990 Sep; 1(1):41-6. PubMed ID: 1669692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.